BI takes interferon-free Hep C combo into Phase III
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim has begun a pivotal Phase III study of its interferon-free triple combination regimen for hepatitis C, containing its investigational products, the protease inhibitor faldaprevir (BI 201335), and its non-nucleoside polymerase inhibitor BI 207127, together with ribavirin.